Oslo, Norway, August 14, 2024 - Nykode Therapeutics ASA (OSE: NYKD), a
clinical-stage biopharmaceutical company dedicated to the discovery and
development of novel immunotherapies, today announced that the United States
Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,059,459,
entitled, "Therapeutic Anticancer Neoepitope Vaccine".

The newly issued patent describes Nykode's fully individualized neoantigen based
vaccine, VB10.NEO, which is in development for the treatment of locally advanced
or metastatic solid tumours. The 20 year expiration date of this patent is
January 5, 2037. Related patents were previously granted to the company in
Russia, India, and Australia.

Michael Engsig, CEO of Nykode, said, 'We are very pleased with the granting of
this important patent in the U.S., a key market for Nykode. Continuously
expanding our patent protection is a core strategy for us. The granting of this
patent is a testament to the world-class innovation taking place in Nykode's
labs. We remain dedicated to pushing the boundaries of what's possible in
medicine, bringing hope to patients and their families around the globe."


About VB10.NEO
VB10.NEO is a proprietary individualized neoantigen vaccine in development for
the treatment of locally advanced or metastatic solid tumors under an exclusive,
worldwide clinical collaboration with Genentech, a member of the Roche Group.
The vaccine is designed to be produced on-demand according to the neoantigen
profile of an individual patient. Neoantigens are proteins generated by
tumor-specific mutations not present in normal tissues and are thus an
attractive target for cancer immunotherapy as they may be recognized as foreign
by the immune system.

Nykode is currently conducting a clinical study evaluating VB10.NEO: VB N-02, an
open-label Phase 1b, dose-escalation study of the safety and antigen-specific
immune responses elicited by VB10.NEO in combination with Roche's checkpoint
inhibitor atezolizumab in patients with locally advanced and metastatic tumors
(NCT05018273).


About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of novel immunotherapies with a focus on the
treatment of cancer and autoimmune diseases. Nykode's modular vaccine technology
specifically targets antigens to antigen presenting cells (APC), which have been
shown to induce a broad, strong and long-lasting antigen specific immune
response in cancer, which correlates with clinical responses.

Nykode's lead product candidates are VB10.16, a therapeutic vaccine for the
treatment of HPV16 induced malignancies which demonstrated favorable safety and
efficacy results from its Phase 2 trial for the treatment of cervical cancer.
VB10.16 is being expanded into multiple trials for treatment of head and neck
cancer and cervical cancer. VB10.NEO, an individualized cancer neoantigen
vaccine, is exclusively out-licensed to Genentech, a member of the Roche Group. 

The Company's partnerships include Genentech within oncology and a multi-target
collaboration with Regeneron in oncology and infectious diseases.

Nykode is also utilizing its APC-targeted technology to create an inverse
vaccine platform for the potential use in autoimmune disorders, organ transplant
rejections, anti-drug antibody reactions and allergy.

Nykode Therapeutics' shares are traded on the Oslo Stock Exchange (OSE: NYKD).
Further information about Nykode Therapeutics can be found at
http://www.nykode.com.


Forward-looking statements for Nykode Therapeutics
This announcement and any materials distributed in connection with this
announcement may contain certain forward-looking statements. By their nature,
forward-looking statements involve risk and uncertainty because they reflect the
company's current expectations and assumptions as to future events and
circumstances that may not prove accurate. A number of material factors could
cause actual results and developments to differ materially from those expressed
or implied by these forward-looking statements.


Contact for Nykode Therapeutics ASA:
Head of Investor Relations, Alexandra Deschner
Nykode Therapeutics ASA 
IR@nykode.com

Nykode Therapeutics ASA
Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway